Ausgabe 2/2023
Inhalt (13 Artikel)
Open Access
short review
Selection of phase II/III breast cancer study highlights at the 2022 ESMO annual meeting
Maximilian Marhold
Open Access
short review
ESMO 2022: spotlight on new emerging treatment options in central nervous system tumors
Maximilian J. Mair, Anna S. Berghoff
Open Access
short review
ESMO update: upper gastrointestinal cancer
Elisabeth S. Bergen, Aysegül Ihan-Mutlu
Open Access
short review
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Christiane G. Mutz-Rabl, Peter Koelblinger, Lukas Koch
Open Access
short review
Lessons learned in adjuvant colorectal cancer
Theresa Schmalfuss, Hossein Taghizadeh
case report
Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report
Clemens Petrasch, Simon Udovica, Frédéric Witte, Bernadette Liegl-Atzwanger, Wolfgang Pokieser, Siroos Mirzaei, Wolfgang Hilbe, Andrea Kaufmann-Keck
short review
Neoadjuvant and adjuvant therapy in early breast cancer. A short review on current clinical approaches
Simon Udovica, Kathrin Strasser-Weippl
original report
Spectrum of renal involvement in MGRS patients: a 6-year study
Poornima Tadkal, Vishwanath Siddini, V. Mahesha, Sudarshan Ballal, Rohan Augustine, Kishore Babu, Mallikarjun Kalashetty
Open Access
position paper
Position paper on CDK4/6 inhibitors in early breast cancer
Michael Gnant, Christian F. Singer, Gabriel Rinnerthaler, Georg Pfeiler, Daniel Egle, Marija Balic, Rupert Bartsch